Purdue, Impax Settle IP Claims In OxyContin Antitrust MDL

Law360, Los Angeles (December 6, 2013, 6:08 PM EST) -- Impax Laboratories Inc. has settled a suit alleging its proposed generic version of OxyContin infringed Purdue Pharma LP's patents for a tamper-resistant version of the painkiller, according to a consent judgment filed Friday in a suit that had been rolled into antitrust multidistrict litigation in New York federal court.

The judgment ends claims brought by Purdue and Grunenthal GmbH in February that Impax’s abbreviated new drug application for generic oxycodone hydrochloride extended-release tablets infringed the plaintiffs’ patents for an abuse-proof, controlled-release version of OxyContin.

Impax agreed not to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.